



Contact:

Joseph Fratantoni, MD
Chief Medical Officer
MaxCyte, Inc.
(301) 517-5556

For Immediate Release

**MaxCyte Presents Novel Approach to Cancer Vaccines with
Late Breaking Abstract at AACR Conference**

Orlando, FL, March 30, 2004 – MaxCyte, Inc., announced today that it will be presenting a study entitled “Efficient Generation of a Cancer Vaccine: Electroloading Dendritic Cells with Whole Tumor Lysate” at the 2004 Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, FL. MaxCyte’s study focuses on generating a dendritic cell-based cancer vaccine using whole tumor lysate.

MaxCyte’s poster will be displayed today at the Late Breaking Abstract Session in Hall B4-D (LB-315) of the Orange County Convention Center from 1pm to 5pm.

About MaxCyte

MaxCyte, Inc. is a clinical stage biotechnology company advancing cell therapy, identifying more targeted ways to deliver drugs, and accelerating drug development with new cell-loading technologies. MaxCyte can load large volumes of any molecule, including drugs, siRNA, nucleic acids and proteins, into any cell rapidly enough to enable on-site patient treatment. The company and its partners have initiated clinical programs in oncology and preclinical and discovery programs in oncology, cardiopulmonary and infectious diseases. For more information including the referenced abstract, visit <http://www.maxcyte.com>.

###